Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
606138-08-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human coagulation factor XIII A-subunit (rFXIII-A2)haemostatic biologic
Mechanism of action
Replaces the deficient factor XIII A-subunit. Factor XIII is activated by thrombin and calcium and cross-links fibrin, stabilising the fibrin clot and supporting resistance to fibrinolysis.
Indications / reported uses
Long-term prophylaxis of bleeding in adults and paediatric patients aged 6 years and older with congenital factor XIII A-subunit deficiency
Treatment of breakthrough bleeding episodes and selected perioperative bleeding prevention in patients receiving prophylaxis, according to product-specific instructions
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Catridecacog Environmental Risk Assessment (ERA) (the Catridecacog ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.